Summary
49.67 -0.21(-0.41%)09/18/2024
CRISPR Therapeutics AG (CRSP)
CRISPR Therapeutics AG (CRSP)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| 0.33 | 9.20 | -0.17 | -18.02 | -30.51 | 4.25 | 0.54 | 252.48 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 49.67 | |
| Open | 50.00 | |
| High | 51.98 | |
| Low | 49.18 | |
| Volume | 1,478,006 | |
| Change | 0.17 | |
| Change % | 0.33 | |
| Avg Volume (20 Days) | 883,434 | |
| Volume/Avg Volume (20 Days) Ratio | 1.67 | |
| 52 Week Range | 37.55 - 91.10 | |
| Price vs 52 Week High | -45.48% | |
| Price vs 52 Week Low | 32.26% | |
| Range | -0.67 | |
| Gap Up/Down | -0.61 | |
Fundamentals | ||
| Market Capitalization (Mln) | 4,223 | |
| EBIDTA | 425,723,008 | |
| PE Ratio | 14.1725 | |
| PEG Ratio | 0.0000 | |
| WallStreet Target Price | 154.61 | |
| Book Value | 32.8640 | |
| Earnings Per Share | 5.2630 | |
| EPS Estimate Current Quarter | -1.7600 | |
| EPS Estimate Next Quarter | -1.8100 | |
| EPS Estimate Current Year | 4.8800 | |
| EPS Estimate Next Year | -7.0400 | |
| Diluted EPS (TTM) | 5.2630 | |
| Revenues | ||
| Profit Marging | 0.4564 | |
| Operating Marging (TTM) | 0.4560 | |
| Return on asset (TTM) | 0.1194 | |
| Return on equity (TTM) | 0.2136 | |
| Revenue TTM | 902,433,984 | |
| Revenue per share TTM | 12.0950 | |
| Quarterly Revenue Growth (YOY) | 4.5680 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | -266,227,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 14.1725 | |
| Forward PE | 23.3645 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 2.2423 | |
| Revenue Enterprise Value | 3.7263 | |
| EBITDA Enterprise Value | 7.8988 | |
| Shares | ||
| Shares Outstanding | 76,527,000 | |
| Shares Float | 72,138,908 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.00 | |
| Insider (%) | 12.95 | |
| Institutions (%) | 54.78 | |
09/18 09:11 EST - seekingalpha.com
Crispr Therapeutics: Prepare To Be Bored
CRISPR Therapeutics' stock may seem boring due to the slow FDA trial and rollout process, but it's a strong long-term investment. CASGEVY, their FDA-approved treatment for sickle cell disease and TDT, will generate revenue soon, with significant growth expected in 2025. The company's future potential lies in its pipeline for cardiovascular disease and cancer treatments, though these remain speculative.
Crispr Therapeutics: Prepare To Be Bored
CRISPR Therapeutics' stock may seem boring due to the slow FDA trial and rollout process, but it's a strong long-term investment. CASGEVY, their FDA-approved treatment for sickle cell disease and TDT, will generate revenue soon, with significant growth expected in 2025. The company's future potential lies in its pipeline for cardiovascular disease and cancer treatments, though these remain speculative.
09/12 08:45 EST - fool.com
1 Biotech Stock Down 62% to Buy and Hold
CRISPR Therapeutics' lone approved product boasts multibillion-dollar revenue potential. Plus, this promising biotech could succeed in launching other breakthrough therapies.
1 Biotech Stock Down 62% to Buy and Hold
CRISPR Therapeutics' lone approved product boasts multibillion-dollar revenue potential. Plus, this promising biotech could succeed in launching other breakthrough therapies.
09/12 04:15 EST - fool.com
3 No-Brainer Biotech Stocks to Buy With $200 Right Now
These companies are innovators and either already have at least one commercialized product or are close to the finish line. One of these players has climbed this year, while the other two have declined -- but they each offer solid long-term share performance potential.
3 No-Brainer Biotech Stocks to Buy With $200 Right Now
These companies are innovators and either already have at least one commercialized product or are close to the finish line. One of these players has climbed this year, while the other two have declined -- but they each offer solid long-term share performance potential.
09/10 18:55 EST - zacks.com
CRISPR Therapeutics AG (CRSP) Laps the Stock Market: Here's Why
The latest trading day saw CRISPR Therapeutics AG (CRSP) settling at $45.51, representing a +1.42% change from its previous close.
CRISPR Therapeutics AG (CRSP) Laps the Stock Market: Here's Why
The latest trading day saw CRISPR Therapeutics AG (CRSP) settling at $45.51, representing a +1.42% change from its previous close.
09/08 12:32 EST - 247wallst.com
2 Biotech Bets to Buy in September
Biotech investing is a thrill-a-minute ride. Biotech stocks can take investors soaring to new heights and fabulous wealth opportunities or send them into the pits of despair.
2 Biotech Bets to Buy in September
Biotech investing is a thrill-a-minute ride. Biotech stocks can take investors soaring to new heights and fabulous wealth opportunities or send them into the pits of despair.
09/05 08:45 EST - fool.com
Down Nearly 50% From Its 52-Week High, Is CRISPR Therapeutics a Steal of a Deal?
CRISPR recently obtained approval for Casgevy, a gene-editing therapy which may generate huge revenue. It could take years, however, before the biotech's bottom line starts to show significant improvement.
Down Nearly 50% From Its 52-Week High, Is CRISPR Therapeutics a Steal of a Deal?
CRISPR recently obtained approval for Casgevy, a gene-editing therapy which may generate huge revenue. It could take years, however, before the biotech's bottom line starts to show significant improvement.
09/04 12:35 EST - zacks.com
Why Is CRISPR Therapeutics (CRSP) Down 7.7% Since Last Earnings Report?
CRISPR Therapeutics (CRSP) reported earnings 30 days ago. What's next for the stock?
Why Is CRISPR Therapeutics (CRSP) Down 7.7% Since Last Earnings Report?
CRISPR Therapeutics (CRSP) reported earnings 30 days ago. What's next for the stock?
09/02 18:15 EST - fool.com
3 Monster Biotech Stocks to Buy Before 2025
Iovance Biotherapeutics is seeing its sales ramp up for the first time. CRISPR Therapeutics has also started to bring in solid revenue.
3 Monster Biotech Stocks to Buy Before 2025
Iovance Biotherapeutics is seeing its sales ramp up for the first time. CRISPR Therapeutics has also started to bring in solid revenue.
08/26 07:30 EST - fool.com
Prediction: These Could Be the Best-Performing Biotech Stocks Through 2030
Viking and CRISPR are both doing work in expanding and lucrative areas. They could deliver market-beating returns if they can avoid major headwinds.
Prediction: These Could Be the Best-Performing Biotech Stocks Through 2030
Viking and CRISPR are both doing work in expanding and lucrative areas. They could deliver market-beating returns if they can avoid major headwinds.
08/19 12:46 EST - zacks.com
CRISPR (CRSP) Loses 24% YTD: How Should You Play the Stock?
Despite gaining regulatory approvals in many countries for the first ever CRISPR-based gene therapy, investors should remain wary of investing in CRISPR Therapeutics' (CRSP) early-stage pipeline.
CRISPR (CRSP) Loses 24% YTD: How Should You Play the Stock?
Despite gaining regulatory approvals in many countries for the first ever CRISPR-based gene therapy, investors should remain wary of investing in CRISPR Therapeutics' (CRSP) early-stage pipeline.
08/14 06:08 EST - seekingalpha.com
Crispr's Casgevy Launch: Promising Start, Uncertain Future
CRISPR Therapeutics' stock has been volatile, with cautious optimism following FDA approval for gene therapy targeting sickle cell disease. Q2 2024 earnings revealed slow commercialization of Casgevy, with revenues significantly below expectations. Financial health of CRISPR is strong, with over 5 years of cash runway, but stock performance has lagged behind S&P 500 returns.
Crispr's Casgevy Launch: Promising Start, Uncertain Future
CRISPR Therapeutics' stock has been volatile, with cautious optimism following FDA approval for gene therapy targeting sickle cell disease. Q2 2024 earnings revealed slow commercialization of Casgevy, with revenues significantly below expectations. Financial health of CRISPR is strong, with over 5 years of cash runway, but stock performance has lagged behind S&P 500 returns.
08/09 10:19 EST - investorplace.com
3 Gene Editing Stocks with Potential to Transform Medicine
Gene editing holds substantial promise for treating thousands of diseases – creating incredible opportunities for gene editing stocks. It could help treat the 7,000 diseases caused by genetic disorders, most of which occur with gene mutation.
3 Gene Editing Stocks with Potential to Transform Medicine
Gene editing holds substantial promise for treating thousands of diseases – creating incredible opportunities for gene editing stocks. It could help treat the 7,000 diseases caused by genetic disorders, most of which occur with gene mutation.
08/08 06:00 EST - investorplace.com
7 Biotech Stocks to Buy for Their Game-Changing Potential
With the market struggling amid rising recession fears, now may be the ideal time to consider biotech stocks. First, the sector itself is a financially lucrative one.
7 Biotech Stocks to Buy for Their Game-Changing Potential
With the market struggling amid rising recession fears, now may be the ideal time to consider biotech stocks. First, the sector itself is a financially lucrative one.
08/07 10:41 EST - seekingalpha.com
Crispr Therapeutics Q2 Earnings: Casgevy Updates Underline 'Blockbuster' Potential
Crispr Therapeutics AG reported no revenues from Casgevy in Q2 earnings, but noted positive progress with over 35 authorized treatment centers activated globally. Casgevy's complex treatment journey involves a lengthy process with no revenue recognition until the end, but the therapy has shown high effectiveness in clinical studies. Crispr Therapeutics and Vertex are working on reducing preconditioning burden for Casgevy patients and exploring the potential of in vivo therapies for the future.
Crispr Therapeutics Q2 Earnings: Casgevy Updates Underline 'Blockbuster' Potential
Crispr Therapeutics AG reported no revenues from Casgevy in Q2 earnings, but noted positive progress with over 35 authorized treatment centers activated globally. Casgevy's complex treatment journey involves a lengthy process with no revenue recognition until the end, but the therapy has shown high effectiveness in clinical studies. Crispr Therapeutics and Vertex are working on reducing preconditioning burden for Casgevy patients and exploring the potential of in vivo therapies for the future.
08/07 09:00 EST - investorplace.com
The 3 Best Gene Editing Stocks to Buy in August 2024
Investing guru Cathie Wood sees precision therapeutics as a massive growth market. She forecasts sales in the category can grow by a compound annual growth rate (CAGR) of 30% through 2030.
The 3 Best Gene Editing Stocks to Buy in August 2024
Investing guru Cathie Wood sees precision therapeutics as a massive growth market. She forecasts sales in the category can grow by a compound annual growth rate (CAGR) of 30% through 2030.
08/06 11:41 EST - zacks.com
CRISPR Therapeutics (CRSP) Q2 Loss Wider Than Expected
CRISPR Therapeutics (CRSP) incurs a wider-than-expected loss in the second quarter of 2024. The commercial launch of CRISPR-based gene therapy, Casgevy, is progressing well.
CRISPR Therapeutics (CRSP) Q2 Loss Wider Than Expected
CRISPR Therapeutics (CRSP) incurs a wider-than-expected loss in the second quarter of 2024. The commercial launch of CRISPR-based gene therapy, Casgevy, is progressing well.
08/05 18:25 EST - zacks.com
CRISPR Therapeutics AG (CRSP) Reports Q2 Loss, Misses Revenue Estimates
CRISPR Therapeutics AG (CRSP) came out with a quarterly loss of $1.49 per share versus the Zacks Consensus Estimate of a loss of $1.37. This compares to loss of $0.98 per share a year ago.
CRISPR Therapeutics AG (CRSP) Reports Q2 Loss, Misses Revenue Estimates
CRISPR Therapeutics AG (CRSP) came out with a quarterly loss of $1.49 per share versus the Zacks Consensus Estimate of a loss of $1.37. This compares to loss of $0.98 per share a year ago.
08/05 16:01 EST - globenewswire.com
CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results
-More than 35 authorized treatment centers (ATCs) activated globally for CASGEVY™ and approximately 20 patients have had cells collected across all regions as of mid-July-
CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results
-More than 35 authorized treatment centers (ATCs) activated globally for CASGEVY™ and approximately 20 patients have had cells collected across all regions as of mid-July-
08/04 06:22 EST - fool.com
Prediction: CRISPR Therapeutics Stock Could Be a Millionaire-Maker
CRISPR Therapeutics' first approval should go on to become massively successful. This approval was a major breakthrough in the area of gene editing.
Prediction: CRISPR Therapeutics Stock Could Be a Millionaire-Maker
CRISPR Therapeutics' first approval should go on to become massively successful. This approval was a major breakthrough in the area of gene editing.
08/01 06:30 EST - fool.com
10 Best Small and Mid-Cap Stocks to Consider Buying in August
Big tech stocks cooled off in July, while smaller growth companies rallied. An anticipated rate cut could amplify this trend reversal in August and beyond.
10 Best Small and Mid-Cap Stocks to Consider Buying in August
Big tech stocks cooled off in July, while smaller growth companies rallied. An anticipated rate cut could amplify this trend reversal in August and beyond.